Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $2.37 in the prior trading day, Oramed Pharmaceuticals, Inc (NASDAQ: ORMP) closed at $2.33, down -1.69%. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 0.51 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ORMP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 27.08 and its Current Ratio is at 27.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Canaccord Genuity on January 12, 2023, Downgraded its rating to Hold and sets its target price to $3 from $30 previously.
On February 18, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.
On April 20, 2021, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $27.Canaccord Genuity initiated its Buy rating on April 20, 2021, with a $27 target price.
Valuation Measures:
As of this moment, Oramed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.38.
Stock Price History:
Over the past 52 weeks, ORMP has reached a high of $3.67, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is -1.12%, while the 200-Day Moving Average is calculated to be -1.83%.
Shares Statistics:
A total of 40.21M shares are outstanding, with a floating share count of 32.34M. Insiders hold about 19.77% of the company’s shares, while institutions hold 19.46% stake in the company.
